SCHEMBL5133471

SCHEMBL5133471

Cc1nc(-c2sc3[nH]c(=O)n(CC(C)C)c(=O)c3c2C)cs1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1A P54750 4/20 0.34
PDE1B Q01064 4/20 0.34
PDE1C Q14123 4/20 0.34
PDE2A O00408 3/20 0.34
ADORA2B P29275 1/20 0.34
KDM4E B2RXH2 5/20 0.32
ERCC5 P28715 1/20 0.32
FEN1 P39748 1/20 0.32
MTOR P42345 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MAPT P10636 1/20 0.32
ALDH1A1 P00352 4/20 0.32
LMNA P02545 1/20 0.32
HTT P42858 1/20 0.32
MAPK1 P28482 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
GFER P55789 1/20 0.31
HPGD P15428 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5130875 0.79 KDM4E (0.33) PDE1APDE1BPDE1CPDE2AADORA2B
SCHEMBL5133074 0.76 ALDH1A1 (0.43) ADORA2BKDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL5132014 0.75 ACACA (0.36)
SCHEMBL5132273 0.74 ALDH1A1 (0.44) ADORA2BKDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL7203074 0.73 MEN1 (0.43) ADORA2BKDM4EERCC5FEN1MAPT
SCHEMBL5132710 0.73 TMIGD3 (0.38) PDE1APDE1BPDE1CADORA2BKDM4E
SCHEMBL5133070 0.73 PDE1A (0.35) PDE1APDE1BPDE1CPDE2AADORA2B
SCHEMBL5132460 0.72 QPCT (0.32) PDE1APDE1BPDE1CPDE2AQPCT
SCHEMBL5132708 0.72 ERCC5 (0.61) PDE1APDE1BPDE1CPDE2AADORA2B
SCHEMBL18097521 0.71 PDE1A (0.34) PDE1APDE1BPDE1CPDE2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989210-A2 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2008-11-12 EP disclosed
WO-2007103776-A2 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2007-09-13 WO disclosed
US-20070208040-A1 e.g. 3-ethyl-5-methyl-1,3-dihydrothiopheno[2,3-d]pyrimidine-2,4-dione; neurodegenerative disorders, antiischemic agent, antidepressant, attention deficit disorder, hepatic fibrosis, cirrhosis of the liver, and drug addiction GILEAD PALO ALTO, INC. 2007-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208040-A1 e.g. 3-ethyl-5-methyl-1,3-dihydrothiopheno[2,3-d]pyrimidine-2,4-dione; neurodegenerative disorders, antiischemic agent, antidepressant, attention deficit disorder, hepatic fibrosis, cirrhosis of the liver, and drug addiction CHRNE, CHRNA3, CHRNA1 PDE1A 538/4885PDE1B 929/4885PDE1C 1268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.